Clinical Trial

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Study acronym: RAMP203
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 12, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Protocol Amendment History 26 amendments
This ClinicalTrials.gov record has been amended 26 times since 2021-09-29; most recent amendment 2026-01-08.
Status change: Recruiting → Active, Not Recruiting 2026-01-08
Status change: Not Yet Recruiting → Recruiting 2022-03-08
Trial Details
NCT Number NCT05074810
Lead Sponsor Verastem, Inc.
Collaborators: Amgen
Conditions Non Small Cell Lung Cancer, KRAS Activating Mutation
Enrollment 153 participants
Start Date 2022-04-12
Primary Completion 2026-06 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-12